Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 161 resultados
LastUpdate Última actualización 06/07/2025 [07:11:00]
pdfxls
Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days
previousPage Resultados 125 a 150 de 161 nextPage  

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CONONAVIRUS SARS-COV-2

NºPublicación:  US2025154231A1 15/05/2025
Solicitante: 
RQBIO COVID LTD [GB]
RQBIO COVID LIMITED
JP_2025507595_A

Resumen de: US2025154231A1

The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

USE OF AMINOPYRIDINE, IN PARTICULAR AMIFAMPRIDINE, FOR THE TREATMENT OF A VIRALLY-ASSOCIATED FATIGUE

NºPublicación:  US2025152566A1 15/05/2025
Solicitante: 
BOEHMEKE THOMAS [DE]
BOEHMEKE Thomas

Resumen de: US2025152566A1

The present invention relates to a new use of an Aminopyridine, such as Pyridine-3,4-diamine, a derivative thereof and/or of a physiologically tolerable salt thereof for the prevention and/or treatment of a fatigue, which is associated with a viral infection, preferably by SARS-CoV-2. In particular for the treatment of fatigue in connection with a “post-COVID phase” and the “long COVID-19 syndrome”.

COMPOSITIONS AND METHODS FOR COVID-19 TREATMENT

NºPublicación:  US2025152613A1 15/05/2025
Solicitante: 
101 THERAPEUTICS LTD [IL]
101 THERAPEUTICS LTD
JP_2025502175_PA

Resumen de: US2025152613A1

Provided herein are compositions for use in treatment fibrosis and in treatment of COVID-19, preferably moderate COVID-19, comprising Compound (1), or a pharmaceutically acceptable salt thereof. Also provided herein are methods for treatment of COVID-19, preferably moderate COVID-19 comprising administering to a patient in need thereof an amount of between 10 mg/day and 30 mg/day, of Compound (1).

ANTIVIRAL NUCLEIC ACIDS AND COMPOSITIONS

NºPublicación:  AU2023366039A1 15/05/2025
Solicitante: 
GRIFFITH UNIV
GRIFFITH UNIVERSITY
AU_2023366039_A1

Resumen de: AU2023366039A1

The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of inhibiting coronavirus (e.g. SARS-CoV-2) replication and their use in treating patients infected by the virus.

NEUTRALIZING ANTIBODIES AGAINST SARS-RELATED CORONAVIRUS

NºPublicación:  US2025154230A1 15/05/2025
Solicitante: 
UNIV ZU KOELN [DE]
UNIVERSIT\u00C4T ZU K\u00D6LN
JP_2024542793_A

Resumen de: US2025154230A1

The present invention relates to antibodies or antigen-binding fragments thereof against SARS-related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.

ANTIVIRAL SULFATED CHITOSAN DERIVATIVES

NºPublicación:  US2025152618A1 15/05/2025
Solicitante: 
CONSEJO SUPERIOR DE INVESTIG CIENTIFICAS CSIC [ES]
UNIV DE VALENCIA [ES]
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC),
UNIVERSITAT DE VAL\u00C8NCIA
WO_2023156349_PA

Resumen de: US2025152618A1

The invention relates to sulfated chitosan derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description, for their use in the treatment and/or prevention of a viral infection, particularly wherein the viral infection is caused by SARS-CoV-2 such as COVID-19 or RSV.

DEVICE AND METHOD FOR PATHOGEN DETECTION

NºPublicación:  US2025155438A1 15/05/2025
Solicitante: 
KING ABDULAZIZ UNIV [SA]
King Abdulaziz University

Resumen de: US2025155438A1

Systems and methods are disclosed herein for pathogen detection employing a lateral flow assay (LFA) device or ELISA assay, e.g. for detecting SARS-COV-2, the virus that causes COVID-19, in a sample. The LFA device includes a nitrocellulose membrane mounted on a solid support, a sample pad for receiving a sample, a conjugate pad containing gold nanoparticles conjugated to heavy chain antibodies (HcAbs), and an absorbent pad at the end of the device.

COMPOSITION FOR POC PCR

NºPublicación:  US2025155436A1 15/05/2025
Solicitante: 
PROCOMCURE BIOTECH GMBH [AT]
PROCOMCURE BIOTECH GMBH
CH_719425_A2

Resumen de: US2025155436A1

Liquid composition for the preparation of a biological sample for methods for assaying for the presence of SARS-COV-2 or genetic variations (mutant) of SARS-COV-2 wildtype in said sample by POC PCR comprising: • a) a chaotropic salt, preferably guanidinium thiocyanate, in a concentration ranging from 1 to 90 mM and • b) optionally one or more RNAse inhibitor.

EXTRACELLULAR VESICLE COMPOSITION FOR USE IN THE TREATMENT OF LONG COVID

NºPublicación:  WO2025101653A1 15/05/2025
Solicitante: 
DIRECT BIOLOGICS LLC [US]
DIRECT BIOLOGICS, LLC
WO_2025101653_PA

Resumen de: WO2025101653A1

Long COVID or Post Acute Sequelae of COVID-19 (PASC), is a prolonged, debilitating syndrome that follows acute SARS-CoV-2 infection in >10% of cases. Human bone marrow mesenchymal stem cell derived extracellular vesicles (hBM-MSC EVs) can present a new therapeutic option.

NOVEL REOVIRUS-BASED VACCINE PLATFORM AND USE THEREOF

NºPublicación:  US2025154204A1 15/05/2025
Solicitante: 
VIROCURE INC [KR]
VIROCURE, INC
WO_2023048532_PA

Resumen de: US2025154204A1

The present invention relates to a novel reovirus-based vaccine platform, and confirmed that a part of the S1 gene of reovirus can be replaced with various exogenous epitope-encoding genes, and a recombinant reovirus manufactured according to the present invention not only can infect target cells and induce the expression of the epitope, but also can effectively prevent and treat diseases related to the epitope by activating the immune function of immune cells against the epitope. When using the reovirus-based vaccine platform of the present invention, vaccines containing various epitopes can be manufactured through relatively simple genetic manipulation technology, and can be administered in various ways including oral administration, so it can be utilized for the prevention and treatment of various infectious diseases including SARS-CoV-2 virus infection, and cancer.

NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES

NºPublicación:  EP4553080A1 14/05/2025
Solicitante: 
USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I [CZ]
Ustav Organicke Chemie a Biochemie AV CR, v.v.i
EP_4553080_PA

Resumen de: EP4553080A1

The invention relates to small molecule inhibitors of formula (I) targeting the nspl4 protein of SARS-CoV-2 and other coronaviruses, for use as antiviral agents directly targeting viral proteins.

SARS-CoV-2 ACE2 Transgenic mouse expressing humanized ACE2 susceptible for SARS-CoV-2 virus infection and production method therefor

NºPublicación:  KR20250067048A 14/05/2025
Solicitante: 
서울대학교산학협력단
WO_2025100882_A1

Resumen de: WO2025100882A1

The present invention discloses: a humanized ACE2-expressing transgenic mouse susceptible to SARS-CoV-2 virus infection, the mouse being obtained by applying a CRISPR system; and a method for producing same. The humanized ACE2-expressing transgenic mouse according to the present invention reflects the severity of symptoms, mortality patterns, and the like according to age, sex, viral infection dose, and the like, as observed in human COVID-19 cases, and reproduces immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain, and thus can be effectively used to understand the pathogenesis of SARS-CoV-2 and to develop vaccines or therapeutic agents.

USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS

NºPublicación:  EP4553084A2 14/05/2025
Solicitante: 
ETHRIS GMBH [DE]
Ethris GmbH
EP_4553084_A2

Resumen de: EP4553084A2

The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.

2 A Immunoglobulin A antibody for neutralizing SARS coronavirus 2 spike antigen and uses thereof

NºPublicación:  KR20250064724A 12/05/2025
Solicitante: 
대한민국질병관리청국립보건연구원장주아이랩

Resumen de: KR20250064724A

본 발명은 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 이뮤노글로불린 A 항체를 제조하여 이를 사스 코로나바이러스 2 검출 또는 진단 용도로 사용하거나 사스 코로나바이러스 2 중화 효과를 기반으로 사스 코로나바이러스 2 감염질환 예방 또는 치료하기 위해 사용하는 용도에 관한 것이다.

2 A Immunoglobulin A antibody for neutralizing SARS coronavirus 2 spike antigen and uses thereof

NºPublicación:  KR20250064725A 12/05/2025
Solicitante: 
대한민국질병관리청국립보건연구원장주아이랩

Resumen de: KR20250064725A

본 발명은 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 이뮤노글로불린 A 항체를 제조하여 이를 사스 코로나바이러스 2 검출 또는 진단 용도로 사용하거나 사스 코로나바이러스 2 중화 효과를 기반으로 사스 코로나바이러스 2 감염질환 예방 또는 치료하기 위해 사용하는 용도에 관한 것이다.

COMPOSITIONS AND METHODS FOR TREATING BIOFILMS AND NEUTROPHIL EXTRACELLULAR TRAP FORMATION

NºPublicación:  AU2023375471A1 08/05/2025
Solicitante: 
RES INSTITUTE AT NATIONWIDE CHILDRENS HOSPITAL
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
AU_2023375471_PA

Resumen de: AU2023375471A1

Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.

USE OF VE607 FOR THE TREATMENT OF SARS-COV-2 INFECTIONS AND RELATED DISEASES

NºPublicación:  US2025144087A1 08/05/2025
Solicitante: 
FINZI ANDRES [CA]
PAZGIER MARZENA [US]
SMITH III AMOS B [US]
DING SHILEI [CA]
MOTHES WALTER [US]
BARON CHRISTIAN [CA]
YANG DEREK [US]
MOHAMMADI MOHAMMADJAVAD [US]
ABRAMS CAMERON [US]
FINZI Andr\u00E9s,
PAZGIER Marzena,
SMITH, III Amos B,
DING Shilei,
MOTHES Walter,
BARON Christian,
YANG Derek,
MOHAMMADI Mohammadjavad,
ABRAMS Cameron
WO_2023147658_PA

Resumen de: US2025144087A1

The present application relates to the use of 3,3′-(1,3-phenylenebis(oxy))bis(1-(piperidin-1-yl)propan-2-ol (VE607) or a pharmaceutically acceptable salt thereof for the inhibition of SARS-CoV-2 and/or management of COVID-19.

PEPTIDE

NºPublicación:  US2025145667A1 08/05/2025
Solicitante: 
QUEEN MARY UNIV OF LONDON [GB]
BARTS HEALTH NHS TRUST [GB]
QUEEN MARY UNIVERSITY OF LONDON,
BARTS HEALTH NHS TRUST
WO_2023099920_A1

Resumen de: US2025145667A1

The present invention relates to peptides derived from COVID-19 virus envelope protein and spike protein. The invention further relates to polynucleotides and vectors encoding said peptides, and antibodies and chimeric antigen receptors that bind to said peptides. The invention also relates to methods of diagnosis and prediction of conditions in a subject which leverage recognition of said peptides, such as by antigen-specific T cells.

THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19

NºPublicación:  US2025144163A1 08/05/2025
Solicitante: 
MOLLICK PETER JOSEPH [US]
Mollick Peter Joseph

Resumen de: US2025144163A1

A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after a patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of an extracted component or a combination of extracted components of an herb thyme leaf also know as common thyme (Thymus Vulgaris). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.

COMPOSITIONS AND METHODS FOR FcRn-TARGETED INTRANASAL CORONAVIRUS VACCINATION

NºPublicación:  US2025144199A1 08/05/2025
Solicitante: 
UNIV OF MARYLAND COLLEGE PARK [US]
UNIVERSITY OF MARYLAND, COLLEGE PARK
WO_2023154402_PA

Resumen de: US2025144199A1

The present disclosure relates generally to novel recombinant coronavirus-based fusion proteins (“RBDs-IgG Fc protein” and “RBDs protein”) and vaccine compositions using the same, in which the fusion proteins comprise tandemly arranged coronaviruses receptor binding domains (RBDs). The present disclosure further provides methods and kits for immunizing a subject using the compositions.

TETANUS VACCINE PLATFORM FOR EMBEDDING COVID-19 VACCINE

NºPublicación:  US2025144201A1 08/05/2025
Solicitante: 
PRIME BIO INC [US]
Prime Bio, Inc
KR_20240031857_PA

Resumen de: US2025144201A1

A method of immunizing against COVID-19 by administering a recombinant SARS-CoV2 protein-based vaccine, developed by either embedding the epitopes/domains, or chemically attaching, to an already established vaccine candidate, e.g., a detoxified recombinant tetanus neurotoxin (DrTeNT). The developed vaccine will have three novel contributions compared to the present vaccine technology: a) providing a novel and very effective vaccine platform; b) priming with DrTeNT will prepare the host immune system for better response; and c) oral delivery of the vaccine candidate with a group of neurotoxin binding proteins (NAPs) from Clostridium sp. A Detoxified recombinant tetanus neurotoxin (DrTeNT) is prepared by mutation of the active site amino acid residues is an effective vaccine candidate, and is used for embedding epitopes of SARS-CoV-2 virus protein for vaccination against Covid-19. DrTeNT is a risk-free vaccine, free of formalin or any other chemical adjuvants.

ACTIVATING ENDOGENOUS ANTIMICROBIALS TO TREAT SARS-COV-2 INFECTION

NºPublicación:  US2025144119A1 08/05/2025
Solicitante: 
EIRGEN PHARMA LTD [IE]
Eirgen Pharma Ltd
JP_2023520591_A

Resumen de: US2025144119A1

Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided.

SARS-CoV-2 USE OF NOVEL POLYMER FOR PREVENTING SARS-COV-2

NºPublicación:  KR20250063018A 08/05/2025
Solicitante: 
포항공과대학교산학협력단대한민국질병관리청국립보건연구원장
US_2025134989_A1

Resumen de: US2025134989A1

The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.

HUMAN MONOCLONAL ANTIBODIES THAT BROADLY TARGET CORONAVIRUSES

NºPublicación:  US2025145690A1 08/05/2025
Solicitante: 
THE U S A AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES [US]
The U.S.A., as represented by the Secretary, Department of Health and Human Services
JP_2025506172_A

Resumen de: US2025145690A1

Disclosed are monoclonal antibodies and antigen binding fragments that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection. In addition, disclosed are methods for detecting a coronavirus in a biological sample, using the disclosed antibodies.

HUMAN MONOCLONAL ANTIBODIES TARGETING THE S2 SUBUNIT OF THE SARS-COV-2 SPIKE PROTEIN

Nº publicación: US2025145691A1 08/05/2025

Solicitante:

BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]
THE UNIV OF NORTH CAROLINA AT CHAPEL HILL [US]
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM,
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

WO_2023159061_A2

Resumen de: US2025145691A1

Provided herein are antibodies and antibody fragments that bind to the S2 subunit of the SARS-CoV-2 spike protein. Methods of treating or preventing SARS-CoV-2 infections are provided, comprising administering to a patient in need thereof an effective amount of a SARS-CoV-2 spike protein S2 subunit-targeting antibody.

traducir